Matthew L Senjem Selected Research

7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indole

11/2022	The Overlap Index as a Means of Evaluating Early Tau PET Signal Reliability.
1/2022	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies.
11/2021	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks.
1/2021	Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.
1/2021	Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy.
1/2021	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation.
11/2020	Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration.
1/2020	Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes.
1/2020	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants.
1/2020	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew L Senjem Research Topics

Disease

73	Alzheimer Disease (Alzheimer's Disease) 11/2022 - 03/2008
42	Dementia (Dementias) 11/2022 - 11/2010
28	Atrophy 06/2022 - 01/2006
25	Cognitive Dysfunction 01/2022 - 11/2010
8	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 01/2021 - 01/2016
8	Amyloidosis 10/2019 - 06/2012
7	Tauopathies 01/2022 - 09/2015
7	Frontotemporal Dementia (Semantic Dementia) 11/2020 - 01/2009
7	Primary Progressive Aphasia 12/2019 - 12/2013
6	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 01/2022 - 01/2006
5	Aphasia (Dysphasia) 04/2022 - 12/2013
4	Amyloid Plaque 01/2021 - 05/2012
3	Multiple Sclerosis 01/2022 - 01/2018
3	Lewy Body Disease (Lewy Body Dementia) 01/2021 - 12/2019
3	Parkinsonian Disorders (Parkinsonism) 01/2021 - 04/2013
3	Corticobasal Degeneration 11/2020 - 01/2018
3	Hypertension (High Blood Pressure) 11/2019 - 04/2014
2	Disease Progression 01/2022 - 10/2018
2	Prodromal Symptoms 01/2021 - 01/2021
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 01/2018
2	Proteostasis Deficiencies 01/2020 - 10/2019
2	Apraxias (Dyspraxia) 01/2016 - 11/2014
2	Language Disorders (Language Disorder) 11/2014 - 03/2014
2	Brain Injuries (Brain Injury) 08/2013 - 04/2013
1	Demyelinating Diseases (Demyelinating Disease) 01/2022
1	Pick Disease of the Brain (Pick's Disease) 11/2020
1	Hippocampal Sclerosis 01/2020
1	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 01/2019
1	Normal Pressure Hydrocephalus 01/2018
1	Parkinson Disease (Parkinson's Disease) 01/2018
1	Neurobehavioral Manifestations 01/2016
1	Vascular Diseases (Vascular Disease) 03/2015
1	Brain Infarction 03/2015
1	Epilepsy (Aura) 03/2014
1	Partial Epilepsies (Epilepsy, Partial) 03/2014
1	Memory Disorders (Memory Loss) 01/2014
1	Synucleinopathies 04/2013
1	Infarction (Infarctions) 04/2013
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 03/2012
1	Motor Neuron Disease (Primary Lateral Sclerosis) 01/2006

Drug/Important Bio-Agent (IBA)

65	Amyloid (Amyloid Fibrils)IBA 04/2022 - 03/2008
50	Biomarkers (Surrogate Marker)IBA 04/2022 - 11/2010
24	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 01/2022 - 05/2012
16	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indoleIBA 11/2022 - 01/2017
13	Apolipoproteins E (ApoE)IBA 06/2022 - 06/2014
10	ApolipoproteinsIBA 06/2022 - 03/2011
8	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2022 - 01/2014
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2009
7	Amyloid beta-PeptidesIBA 01/2021 - 11/2010
4	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2018 - 12/2014
3	LigandsIBA 01/2022 - 01/2019
3	Biological ProductsIBA 01/2021 - 07/2019
3	Apolipoprotein E4IBA 12/2019 - 12/2015
3	N 30IBA 01/2018 - 01/2009
2	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2022 - 08/2012
2	IronIBA 01/2021 - 01/2021
2	Glucose (Dextrose)FDA LinkGeneric 11/2019 - 01/2018
2	Protons (Proton)IBA 06/2014 - 07/2013
2	ProgranulinsIBA 03/2014 - 03/2012
2	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 03/2012 - 01/2009
1	Cholinergic Agents (Cholinergics)IBA 01/2022
1	Carrier Proteins (Binding Protein)IBA 01/2022
1	Protein Isoforms (Isoforms)IBA 01/2022
1	SynucleinsIBA 11/2021
1	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 01/2021
1	2- carbomethoxy- 8- (3- fluoropropyl)- 3- (4- iodophenyl)tropaneIBA 01/2021
1	antineoplaston A10 (A 10)IBA 01/2021
1	Prostaglandins FIBA 01/2020
1	Carbon-11IBA 12/2019
1	17-hydroxyestrane-3-carbonitrile (ECN)IBA 01/2017
1	flutemetamolIBA 01/2017
1	Hormones (Hormone)IBA 01/2016
1	CarbonIBA 12/2014
1	Pharmaceutical PreparationsIBA 03/2014
1	Coloring Agents (Dyes)IBA 05/2012
1	SilverIBA 05/2012
1	AD 20 (AD-20)IBA 03/2011
1	DNA (Deoxyribonucleic Acid)IBA 01/2009
1	UbiquitinIBA 01/2006

Therapy/Procedure

2	Therapeutics 01/2016 - 09/2015
1	Salpingo-oophorectomy 01/2019
1	Activities of Daily Living (ADL) 01/2016
1	Secondary Prevention 10/2012